Literature DB >> 34245399

Pancreatic MR imaging and endocrine complications in patients with beta-thalassemia: a single-center experience.

Cihangir Sevimli1, Yasin Yilmaz2, Zuhal Bayramoglu3, Rana Gunoz Comert3, Nurdan Gul4, Memduh Dursun3, Zeynep Karakas5.   

Abstract

Iron deposition in various organs can cause endocrine complications in patients with transfusion-dependent beta-thalassemia. The aim was to investigate the relationship between endocrine complications and pancreatic iron overload using magnetic resonance imaging (MRI). Forty patients with transfusion-dependent thalassemia (TDT) were enrolled in the study. The magnetic resonance imagings of the patients were performed using a 1.5 Tesla Philips MRI scanner. Two out of three patients had at least one clinical endocrine complication. The rate of iron deposition was 62.5% in liver, and 45% in pancreas tissue, and was 12.5% in heart tissue. Pancreatic T2* and hepatic T2* values were significantly positively correlated (p = 0.006). Pancreatic T2* and ferritin were significantly negatively correlated (p = 0.03). Cardiac T2* values were negatively correlated with fasting blood glucose (p = 0.03). Patients with short stature had significantly higher cardiac iron burden (22.3 vs. 36.6 T2*ms; p 0.01), and patients with hypothyroidism had higher liver iron concentrations (9.9 vs. 6.4 LIC mg/g; p = 0.05). The ferritin level of 841 ng/mL and liver iron concentration (LIC) value of 8.7 mg/g were detected as the threshold level for severe pancreatic iron burden (AUC 70%, p:0.04, AUC 80%, p = 0.002, respectively). Moreover, males were found to have decreased pancreas T2* values compared with the values in females (T2* 19.3 vs. 29.9, p = 0.05). Patients with higher ferritin levels over than 840 ng/mL should be closely monitored for pancreatic iron deposition, and patients with endocrine complications should be assessed in terms of cardiac iron burden.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Endocrine complications; Pancreas MRI; Transfusion-dependent thalassemia

Mesh:

Substances:

Year:  2021        PMID: 34245399     DOI: 10.1007/s10238-021-00735-7

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  6 in total

1.  Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia.

Authors:  Vincenzo De Sanctis; Malgorzata Roos; Theo Gasser; Monica Fortini; Giuseppe Raiola; Maria Concetta Galati
Journal:  J Pediatr Endocrinol Metab       Date:  2006-04       Impact factor: 1.634

2.  The Close Link of Pancreatic Iron With Glucose Metabolism and With Cardiac Complications in Thalassemia Major: A Large, Multicenter Observational Study.

Authors:  Alessia Pepe; Laura Pistoia; Maria Rita Gamberini; Liana Cuccia; Angelo Peluso; Giuseppe Messina; Anna Spasiano; Massimo Allò; Maria Grazia Bisconte; Maria Caterina Putti; Tommaso Casini; Nicola Dello Iacono; Mauro Celli; Angelantonio Vitucci; Pietro Giuliano; Giuseppe Peritore; Stefania Renne; Riccardo Righi; Vincenzo Positano; Vincenzo De Sanctis; Antonella Meloni
Journal:  Diabetes Care       Date:  2020-09-04       Impact factor: 19.112

3.  Morbidity and mortality patterns of thalassaemia major patients in Hong Kong: retrospective study.

Authors:  C K Li; C W Luk; S C Ling; K W Chik; H L Yuen; C K Li; M M K Shing; K O Chang; P M P Yuen
Journal:  Hong Kong Med J       Date:  2002-08       Impact factor: 2.227

4.  Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF).

Authors:  Vincenzo De Sanctis; Androulla Eleftheriou; Cristina Malaventura
Journal:  Pediatr Endocrinol Rev       Date:  2004-12

5.  Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.

Authors:  Maria Rita Gamberini; Vincenzo De Sanctis; Giuseppe Gilli
Journal:  Pediatr Endocrinol Rev       Date:  2008-10

6.  Thalassaemia and aberrations of growth and puberty.

Authors:  Andreas Kyriakou; Nicos Skordis
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-07-27       Impact factor: 2.576

  6 in total
  1 in total

Review 1.  New Entity-Thalassemic Endocrine Disease: Major Beta-Thalassemia and Endocrine Involvement.

Authors:  Mara Carsote; Cristina Vasiliu; Alexandra Ioana Trandafir; Simona Elena Albu; Mihai-Cristian Dumitrascu; Adelina Popa; Claudia Mehedintu; Razvan-Cosmin Petca; Aida Petca; Florica Sandru
Journal:  Diagnostics (Basel)       Date:  2022-08-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.